Can ‘Long-Term Partner’ Cipla Breathe New Life Into MannKind’s Afrezza?
Cipla is to commercialize the financially troubled MannKind’s inhaled insulin Afrezza in India, but it remains to be seen whether the deal can materially change the fortunes of the product.
You may also be interested in...
Genentech and Lodo will mine the soil microbiome to discover novel therapeutics. China’s Luye licenses commercial rights to AstraZeneca’s Seroquel franchise, while Sarepta picked up rights to gene therapy candidates from Myonexus, plus an option to acquire the company.
Sanofi has launched its next generation basal insulin, Toujeo, on the Indian market at a significantly reduced per unit price point versus Novo Nordisk’s Tresiba (insulin degludec), setting the stage for an interesting market expansion battle.
Six months ago it seemed as though the sky was falling for small drug developer MannKind, when its big pharma licensing partner, Sanofi, pulled out of their deal for the manufacture and distribution of approved inhaled insulin therapy, Afrezza. However, MannKind Corp. made rapid changes to evolve its business into a specialty pharmaceutical company and took back the drug to market on its own – a feat it had never performed before.